Hyperbaric Oxygen Therapy Raises the Bar in Wound Care Treatment by Daniel Rose, M.D.
More than six million people in the United States suffer from chronic wounds – skin disruptions that do not show significant improvement within four weeks or heal completely within eight weeks.
Chronic wounds typically fall into one of the following categories:
Venous stasis ulcers
Delayed radiation injury
Pressure ulcers (commonly known as bed sores)
Ulcers on ischemic limbs
Other chronic, hard-to-heal wounds
Daniel Rose, M.D.
The treatment of chronic wounds poses a significant challenge for medical professionals. To meet this challenge in Sonoma, Lake, and Mendocino Counties, Healdsburg District Hospital has developed Northern California Wound Care and Hyperbarics, a comprehensive multidisciplinary team focused solely on the treatment of chronic, non-healing wounds. As an essential part of this initiative, HDH now offers hyperbaric oxygen therapy (HBOT) using two state-of-the-art chambers. Of the patients treated at Northern California Wound Care and Hyperbarics, about 15% will require HBOT.
Hyperbaric or high-pressure therapy without oxygen dates back to 1662, when it was used unsuccessfully to treat rickets, scurvy, and arthritis. A century after the discovery of oxygen in 1775, it was combined with pressure to study its effects on experimental animals. Oxygen toxicity became readily apparent as seizures and pulmonary damage occurred.
Beginning in 1937, hyperbaric oxygen was used to treat divers who spent too much time underwater and surfaced too rapidly. A 1966 coal mine disaster in Japan ushered in the wound-healing era of HBOT. Miners with thermal burns and carbon monoxide poisoning were treated in an HBOT chamber, and their skin healed significantly better than those treated conventionally.
Through the 1960s, HBOT was applied to a multitude of unrelated chronic ailments. The lack of proven efficacy of HBOT for these conditions resulted in a backlash of skepticism against this treatment modality.
Finally, in 1976, the Undersea and Hyperbaric Medical Society developed a list of scientifically proven indications for HBOT:
Air or gas embolism
Carbon monoxide or cyanide poisoning
Clostridial myositis and myonecrosis (gas gangrene)
Medical indications for HBOT have expanded in recent decades. In the United States, the number of hyperbaric oxygen chambers has grown from 37 in 1977 to more than 800 today.
How HBOT works
Treatment consists of placing the patient in a specially designed clear plastic pressure chamber. Once the chamber’s hatch is closed, the patient breathes 100% oxygen at twice normal atmospheric pressure. Because of the risk of fire, the patient is dressed in a plain cotton gown, and takes nothing into the chamber except a bottle of drinking water. A grounding strap is worn on the wrist to prevent the building of static electricity and a spark. Hearing aids, dentures, and medication patches are all removed before the treatment, which normally lasts two hours. A course of therapy typically requires 30 “dives” over a period of six weeks, though acute conditions (thermal burns, compromised grafts, or carbon monoxide poisoning) may need just a few.
Under normal atmospheric conditions, oxygen is simply a requirement of metabolism. At higher pressures and concentrations, its physiologic effects increase. For example, in a patient with bends, gas embolism, or gas gangrene, high-pressure oxygen compresses the gas bubbles trapped in capillaries and tissues, restoring normal blood flow. At three times atmospheric pressure, sufficient oxygen is dissolved in plasma that the body’s resting metabolic needs can be met without hemoglobin. Failing grafts and skin flaps, severe anemia, and vascular insufficiency all respond to this mechanism of action.
Vasoconstriction caused by HBOT reduces capillary hydrostatic pressure and edema in crush injury and compartment syndrome. High oxygen concentration allows this metabolite to diffuse farther outside capillaries spread apart by edema fluid, thus reaching hypoxic cells. High oxygen gradients stimulate new growth of blood vessels to help heal diabetic foot ulcers and radiation damaged tissue. Even brief exposure to hyperbaric oxygen causes fibroblasts to increase collagen production to create the framework for reconstruction.
HBOT doubles the killing power of hypoxic white blood cells. This process inhibits anaerobic bacteria, suppresses exotoxins and destroys some clostridia and cytolytic toxins. Transport of certain antibiotics across bacterial cell walls is also enhanced, causing these drugs to work more efficiently. In addition, intracranial abscesses, invasive mycoses, and chronic foot ulcers can respond to the anti-infective mechanisms of HBOT.
Risks And Contraindications
HBOT’s numerous benefits do not come without risks. Pressure changes can injure the middle and inner ear as trapped air contracts and expands. Barotraumas can also create or worsen pnemothorax, cause sinus pain, and damage certain older implanted devices such as pacemakers. Some patients experience confinement anxiety, or claustrophobia, during the first few treatments. This symptom can be alleviated with emotional support, reassurance, or medication. Diabetic patients can become hypoglycemic with HBOT, as glucose uptake by muscle cells accelerates. These individuals must test with a pretreatment blood sugar of at least 120 before entering the chamber. Oxygen toxicity causes seizures once in every 10,000 exposures, even in patients who have successfully completed previous treatments. Paresthesias occur commonly, but resolve after therapy is completed. Pulmonary toxicity is rare in the outpatient setting, but alveolar edema, hyaline membrane formation, and interstitial fibrosis can occur with more intensive regimens. Existing cataracts can be worsened by HBOT, but treatment does not typically cause new cataracts if the treatment regimen is fifty applications or fewer. One-third of patients will become temporarily nearsighted after two weeks of treatments, but this symptom resolves spontaneously within several months.
Some patients are excluded from HBOT. Untreated pneumothorax or a history of spontaneous pneumothorax are absolute contraindications. Any prior bleomycin treatment creates a risk of interstitial pneumonitis. Recent administration of cisplatin, carboplatin, or doxorubicin requires postponement of therapy. Disulfiram (Antabuse) and mefanide (Sulfamylon) increase the risk of oxygen toxicity seizures. Relative contraindications include seizure disorders, high fever, severe COPD, CHF, and history of thoracic surgery, although most of these can be managed though a course of treatment.
HBOT is expensive – a course of 30 outpatient treatments can cost $40,000 or more. Despite the cost, HBOT is life-saving and limb-saving therapy. Prospective, randomized controlled trials demonstrate a 75% reduction in major amputations for advanced diabetic foot ulcers. HBOT is the only effective treatment for delayed radiation injury disease. Medicare, Medicaid, and most major insurance carriers cover the list of indications approved by the Undersea and Hyperbaric Medical Society.
Standard wound care, not HBOT, is still the mainstay for 85% of patients who present to Northern California Wound Care and Hyperbarics. This hospital-based, physician-directed program employs a multidisciplinary team to treat diabetic ulcers, delayed radiation injury, arterial and venous ulcers, chronic osteomyelitis, thermal burns, failing grafts, and other problem wounds. The medical professionals at Northern California Wound Care and Hyperbarics provide meticulous attention to circulation, debridement, infection control, wound bed moisture, mechanical protection, compression, neuropathy, and malignancy. Referrals from physicians, nurses, institutions, and patients themselves are accepted.
About The Author
Daniel Rose, M.D., is the medical director of Northern California Wound Care and Hyperbarics. Dr. Rose received his M.D. degree from the University of California in San Francisco and has practiced as a Family Physician in Healdsburg since 1974.
During his career, Dr. Rose has participated in the care of more than 5,000 surgical patients. His research activities include development of the nicotine skin patch and long-acting sunscreens.
The Northern California Wound Care and Hyperbarics Team includes:
Daniel Rose, M.D.
Gary LeKander, M.D., F.C.C.P.
Mujeeb Altaf, M.D.
Bruce Deas, M.D.
Walter Maack, M.D.
Rachel Hoval, D.P.M.
Karis Van der Zee Gradek, RN
Thomas Briones, Certified Hyperbaric Therapist
Northern California Wound Care and Hyperbarics is a satellite office of Healdsburg District Hospital and is located at 1540 Healdsburg Avenue in Healdsburg. The team can be reached by calling Sherill Campos, Office Coordinator, at (707) 473-4404. Facility tours can be arranged with advanced notice.